ArticleCellular and molecular gastroenterology and hepatology2020
Virus-Host Interactions Between Nonsecretors and Human Norovirus.
Article in Cellular and molecular gastroenterology and hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Association Between ABO or Rh Blood Groups and Chikungunya Virus Infection: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Norovirus replication, host interactions and vaccine advances.Nature reviews. Microbiology · 2025Review
- H and B Blood Antigens Are Essential for In Vitro Replication of GII.2 Human Norovirus.Open forum infectious diseases · 2025Article
- Biological and immunological characterization of major capsid protein VP1 from distinct GII.2 norovirus clusters.Scientific reports · 2024Article
- Review
- Human intestinal organoids as models to study enteric bacteria and viruses.Current opinion in microbiology · 2023Review
- Linear epitopes on the capsid protein of norovirus commonly elicit high antibody response among past-infected individuals.Virology journal · 2023Article
- CLIC and membrane wound repair pathways enable pandemic norovirus entry and infection.Nature communications · 2023Article
- Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model Inoculum.The Journal of infectious diseases · 2022Article
- Article
- Profiling of humoral immune responses to norovirus in children across Europe.Scientific reports · 2022Article
- Prevaccination Glycan Markers of Response to an Influenza Vaccine Implicate the Complement Pathway.Journal of proteome research · 2022Article
- Advances in understanding of the innate immune response to human norovirus infection using organoid models.The Journal of general virology · 2022Review
- Norovirus Vaccines: Current Clinical Development and Challenges.Pathogens (Basel, Switzerland) · 2021Review
- Glycan Recognition in Human Norovirus Infections.Viruses · 2021Review
- Serological Humoral Immunity Following Natural Infection of Children with High Burden Gastrointestinal Viruses.Viruses · 2021Review
- Review
- Bile Goes Viral.Viruses · 2021Review
- Article
- Roles of bile acids in enteric virus replication.Animal diseases · 2021Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsHuman norovirus infection is the leading cause of acute gastroenteritis. Genetic polymorphisms, mediated by the FUT2 gene (secretor enzyme), define strain susceptibility. Secretors express a diverse set of fucosylated histoblood group antigen carbohydrates (HBGA) on mucosal cells; nonsecretors (FUT2
methodsBy using specimens collected from the first characterized nonsecretor cohort naturally infected with GII.2 human norovirus, we evaluated the breadth of serologic immunity by surrogate neutralization assays, and cellular activation and cytokine production by flow cytometry.
resultsGII.2 infection resulted in broad antibody and cellular immunity activation that persisted for at least 30 days for T cells, monocytes, and dendritic cells, and for 180 days for blocking antibody. Multiple cellular lineages expressing interferon-γ and tumor necrosis factor-α dominated the response. Both T-cell and B-cell responses were cross-reactive with other GII strains, but not GI strains. To promote entry mechanisms, inclusion of bile acids was essential for GII.2 binding to nonsecretor HBGAs.
conclusionsThese data support development of within-genogroup, cross-reactive antibody and T-cell immunity, key outcomes that may provide the foundation for eliciting broad immune responses after GII.4 vaccination in individuals with limited GII.4 immunity, including young children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.